Loading...
Targeting B Cells to Modify MS, NMOSD, and MOGAD: Part 1
Ocrelizumab, rituximab, ofatumumab, ublituximab, inebilizumab, and evobrutinib are immunotherapies that target various B cell–related proteins. Most of these treatments have proven efficacy in relapsing and progressive forms of MS and neuromyelitis optica spectrum disease (NMOSD), or are in advanced...
Na minha lista:
| Udgivet i: | Neurol Neuroimmunol Neuroinflamm |
|---|---|
| Main Authors: | , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Lippincott Williams & Wilkins
2020
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8063619/ https://ncbi.nlm.nih.gov/pubmed/33406479 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1212/NXI.0000000000000918 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|